Short of a biochemical analysis by a certified laboratory employing verified phytocannabinoids standards, the cannabis consumer can have no real idea of the composition or consistency of the product that they purchase. “Strain names” are eminently malleable, and are as simple to alter as writing a new label to change one to match the most desirable chemovar du jour. doi: 10.1097/010000125688.05091.8f Pub Med Abstract | Cross Ref Full Text | Google Scholar Notcutt, W., Langford, R., Davies, P., Ratcliffe, S., and Potts, R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). Other routes of administration, e.g., transdermal patches and rectal suppositories have not yet demonstrated practicality in later stage clinical trials (Huestis, 2007). A multi-center, double-blind, randomized, placebo-controlled trial of oro-mucosal cannabis-based medicine in the treatment of neuropathic pain characterized by allodynia. A cannabis delivery system with reliable intermediate onset, allows dose titration without pulmonary dangers, relieves symptoms, and is biochemically uniform and defined would engender confidence of all parties. Other cannabis-based medicines that follow will necessarily be required to meet similar benchmarks. doi: 10.1111/j.1468-1331.2010.03328.x Pub Med Abstract | Cross Ref Full Text | Google Scholar Nurmikko, T. It is the widespread belief of most scientists and many legal scholars that the only viable solution to the issues of medicinal cannabis is a pharmaceutical approach.
Such an approach can remove the current clandestine atmosphere surrounding cannabis and promote the kind of open and mutual therapeutic doctor-patient relationship, while maintaining legal status. doi: 10.1017/S1463423612000333 Pub Med Abstract | Cross Ref Full Text | Google Scholar Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., and et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Is there a pathway that will lead to the return of cannabis to mainstream medicine? Neuropsychological performance in long-term cannabis users. The answer is clear, inasmuch as it has already commenced. Rather, what is necessary is more complete data on a given chemovar's biochemistry and attributable pharmacology. One sophisticated approach to the issue combining those quantitative assays with additional subjective data on scent, taste and effects, dubbed Phyto Facts, has recently been described (Giese et al., 2015). doi: 10.1016/S0001-4575(03)00084-8 Pub Med Abstract | Cross Ref Full Text | Google Scholar Müller-Vahl, K. The problem is compounded by the facts that technically almost all laboratories pursuing phytocannabinoid analyses in the USA are doing so illegally, most without benefit of a Schedule I license from the Drug Enforcement Administration (DEA). Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults.